ARTICLE | Company News
FDA approves Kythera's double-chin treatment
April 30, 2015 1:52 AM UTC
FDA approved an NDA for Kybella deoxycholic acid from Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) to reduce submental (under chin) fat.
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted 17-0 in March to back Kybella's approval. The company did not respond to inquiries regarding the drug's price. It said it expects to begin training physicians in June on the safe use of Kybella before sales begin (see BioCentury Extra, March 9). ...